Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Carcinoma, Non-Small-Cell Lung 147Breast Neoplasms 116Prostatic Neoplasms 61Multiple Myeloma 56Neoplasms 55Lung Neoplasms 49Neoplasm Metastasis 44Parkinson Disease 4, Autosomal Dominant Lewy Body 36Ovarian Neoplasms 35Colorectal Neoplasms 35Leukemia, Lymphocytic, Chronic, B-Cell 32Carcinoma, Renal Cell 27Recurrence 26Leukemia, Myeloid, Acute 26Urinary Bladder Neoplasms 25Carcinoma, Hepatocellular 24Small Cell Lung Carcinoma 22Myasthenia Gravis 22Triple Negative Breast Neoplasms 21Endometrial Neoplasms 21Squamous Cell Carcinoma of Head and Neck 20Lymphoma, Large B-Cell, Diffuse 20Nasopharyngeal Carcinoma 18Melanoma 18Lymphoma, Follicular 18Stomach Neoplasms 17Fallopian Tube Neoplasms 17Non-Muscle Invasive Bladder Neoplasms 16Brain Neoplasms 16Pancreatic Neoplasms 15

Interventions

luspatercept 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × beta-Thalassemia × 90 days × Clear all
NCT04064060 2026-05-28

A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials

Celgene

Phase 3 Recruiting
665 enrolled
Myeloid

Myelodysplastic Syndromes, Myeloproliferative Disorders, beta-Thalassemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡